Investigating a new treatment for seizures using a specific inhibitor in mice
Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
This study is looking at a special treatment that might help reduce seizures in mice with epilepsy by blocking a protein that could be causing brain damage, and the researchers want to see if giving this treatment through the nose can make a difference.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuraegis, INC. NIH-funded |
| Lab location | 1 site (Irvine, UNITED STATES) |
| Project ID | NIH-10913326 on NIH RePORTER |
What this research studies
This research focuses on testing a selective calpain-2 inhibitor to see how it affects spontaneous recurrent seizures in mouse models of epilepsy. The study aims to understand the role of calpains, which are proteins that may contribute to neuronal damage and seizure activity. By using a specific inhibitor, the researchers hope to reduce seizure frequency and improve outcomes for epilepsy. The approach involves administering the inhibitor intranasally to assess its effectiveness in preventing seizures.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals with epilepsy, especially those experiencing drug-resistant seizures.
Not a fit: Patients who do not have epilepsy or those whose seizures are well-controlled with existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with epilepsy, particularly those who do not respond to current medications.
How similar studies have performed: Previous studies have shown promise in using calpain inhibitors to reduce seizure development, indicating a potential for success in this approach.
Where this research is happening
Irvine, UNITED STATES
- Neuraegis, INC. — Irvine, United States (Active)
Researchers
- Principal investigator: Baudry, Michel — Neuraegis, INC.
- Study coordinator: Baudry, Michel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.